Anebulo Pharmaceuticals, Inc.
ANEB- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001815974
No open-market purchases or sales by Anebulo Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Anebulo Pharmaceuticals, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 18 | 21 | +3 |
| Shares | 22.6M | 22.2M | −372.1K (−1.6%) |
| Value | $32.5M | $55.5M | +$23.0M (+70.8%) |
New holders (9)
Institutions that held Anebulo Pharmaceuticals, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 28,500 | $71.3K | 0.00% |
| Northern Trust Corp | 24,393 | $61.0K | 0.00% |
| Rangeley Capital, LLC | 20,000 | $50.0K | 0.05% |
| XTX Topco Ltd | 19,153 | $47.9K | 0.00% |
| State Street Corp | 12,768 | $31.9K | 0.00% |
| JPMorgan Chase & Co | 2,138 | $5.34K | 0.00% |
| Barclays PLC | 399 | $998 | 0.00% |
| Citigroup Inc | 6 | $15 | 0.00% |
| FNY Investment Advisers, LLC | 95 | $0 | 0.00% |
Sold out (6)
Institutions that held Anebulo Pharmaceuticals, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| LVW Advisors, LLC | 349,617 | $503.4K |
| Millennium Management LLC | 153,809 | $221.5K |
| Citadel Advisors LLC | 25,017 | $36.0K |
| Goldman Sachs Group Inc | 11,600 | $16.7K |
| The PNC Financial Services Group, Inc. | 1,528 | $2.20K |
| Ameritas Advisory Services, LLC | 10 | $14 |